CA-MFA
9.9.2021 16:45:08 CEST | Business Wire | Press release
MFA , an international organization championing the global industry adoption of private networks, is gaining industry momentum with the recent certification of the Nokia Industrial MulteFire fieldrouter 700 and announcement of Uni5G Technology Blueprints. The Nokia MulteFire solution , which is available for deployment with Nokia Digital Automation Cloud, will enable MulteFire LTE-based private network adoption worldwide, unlocking access to unlicensed spectrum. With deployment available globally, it can be used by small and medium enterprises without access to licensed spectrum and it can bring additional capacity as a complementary layer to wireless networks and enable new nomadic use cases to advance Industry 4.0.
In addition to supporting 4.9G/LTE private networks, MFA recently announced its expansion to 5G with Uni5G Technology Blueprints, which help provide guidance to enterprises looking to deploy 5G private networks. MFA is also developing best practices and targeted guides to help industry verticals implement the key 3GPP 5G specification features that are relevant to their specific deployment.
The MFA Certification Program ensures that devices have implemented the MulteFire specifications correctly and are able to interoperate with devices from other manufacturers.
“The Nokia MulteFire solution has passed rigorous interoperability testing at our Authorized Test Lab DEKRA,” said Scott Fischel, MFA Certification Group Chair. “We congratulate Nokia on delivering the world’s first MulteFire Certified end-to-end solution that will provide end-users with confidence that it can meet the robust connectivity requirements offered by MulteFire 4.9G/LTE private wireless.”
“Private 5G and LTE networks are a rapidly growing market and will account for over $5B in global enterprise expenditure by 2025,” said Pablo Tomasi, Principal Analyst, Private Networks, Omdia. “MFA aims to support and accelerate the private 5G networks market through both this certification program and by tackling the issue of replicability and complexity through the delivery of Uni5G Technology Blueprints developed to simplify deployment for different industry verticals.”
The MFA Certification Program is available to MFA members, and it will help facilitate further expansion of the MulteFire private wireless ecosystem. For companies interested in joining the MFA, visit www.mfa-tech.org/become-a-member .
Resources:
- Interview: Meet MFA Certificate Authority
- Interview: Meet MFA Authorized Test Lab – DEKRA
- Video: Uni5G and MulteFire Private Networks for Manufacturing
- Press Release: MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise
- White Paper: “5G Private Networks for Maritime Use Opportunities for Digital Port Automation ,” Beecham Research
- White Paper: “The Importance of Spectrum Liberalization for Private 5G Networks,” ABI Research
About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005742/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom